| 23.04 -1.48 (-6.04%) | 07-10 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 29.45 | 1-year : | 34.4 |
| Resists | First : | 25.21 | Second : | 29.45 |
| Pivot price | 22.53  |
|||
| Supports | First : | 19.59 | Second : | 16.11 |
| MAs | MA(5) : | 23.85 |
MA(20) : | 21.38 |
| MA(100) : | 18.7 |
MA(250) : | 14.66 |
|
| MACD | MACD : | 1.4 |
Signal : | 1.3 |
| %K %D | K(14,3) : | 81.9 |
D(3) : | 84.5 |
| RSI | RSI(14): 59.5 |
|||
| 52-week | High : | 25.77 | Low : | 4.11 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ GLUE ] has closed below upper band by 43.7%. Bollinger Bands are 96.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 24.23 - 24.35 | 24.35 - 24.44 |
| Low: | 21.99 - 22.14 | 22.14 - 22.27 |
| Close: | 22.82 - 23.06 | 23.06 - 23.25 |
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
Fri, 10 Jul 2026
Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price Down 8.7% - Here's What Happened - MarketBeat
Thu, 09 Jul 2026
Monte Rosa Therapeutics (GLUE) Recast As A Growth Name As Valuation Questions Build - simplywall.st
Wed, 08 Jul 2026
T. Rowe Price reports 8.86M-share stake in Monte Rosa Therapeutics (GLUE) - Stock Titan
Tue, 07 Jul 2026
Monte Rosa Therapeutics CSO Sharon Townson sells shares worth $139,849 - Investing.com
Tue, 07 Jul 2026
Monte Rosa Therapeutics (GLUE) CSO sells 6,000 shares after option exercise - Stock Titan
Tue, 07 Jul 2026
Monte Rosa Therapeutics (NASDAQ:GLUE) Trading Up 6.9% - Should You Buy? - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 84 (M) |
| Held by Insiders | 5.3e+007 (%) |
| Held by Institutions | 0.5 (%) |
| Shares Short | 14,960 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.3994e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 188.4 % |
| Return on Equity (ttm) | -16.5 % |
| Qtrly Rev. Growth | 4.295e+007 % |
| Gross Profit (p.s.) | -59.38 |
| Sales Per Share | -20.39 |
| EBITDA (p.s.) | -6.40375e+007 |
| Qtrly Earnings Growth | -1.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -1.14 |
| Price to Cash Flow | 5.95 |
| Dividend | 0 |
| Forward Dividend | 1.717e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|